



Walgreens Boots Alliance Inc. (WBA)

Updated June 27th, 2024, by Aristofanis Papadatos

Key Metrics

Current Price:	\$15	5 Year CAGR Estimate:	20.3%	Market Cap:	\$13 B
Fair Value Price:	\$27	5 Year Growth Estimate:	4.0%	Ex-Dividend Date¹:	8/16/24
% Fair Value:	56%	5 Year Valuation Multiple Estimate:	12.2%	Dividend Payment Date:	9/10/24
Dividend Yield:	6.7%	5 Year Price Target	\$32	Years Of Dividend Growth:	0
Dividend Risk Score:	B	Retirement Suitability Score:	A	Rating:	Buy

Overview & Current Events

Walgreens Boots Alliance is the largest retail pharmacy in both the United States and Europe. Through its flagship *Walgreens* business and other business ventures, the \$13 billion market cap company has a presence in 9 countries, employs more than 330,000 people and has about 12,500 stores in the U.S., Europe, and Latin America.

On June 27th, 2024, Walgreens reported results for the third quarter of fiscal 2024. Sales grew 3% but earnings-per-share decreased 36% over last year's quarter, from \$0.99 to \$0.63, due to intense competition, which has eroded profit margin. Earnings-per-share missed the analysts' consensus by \$0.08. Walgreens has exceeded the analysts' estimates in 13 of the last 16 quarters. However, as the pandemic has subsided and competition has heated in the retail pharmaceutical industry, Walgreens is facing tough comparisons. It lowered its guidance for earnings-per-share in 2024 from \$3.20-\$3.35 to \$2.80-\$2.95. Accordingly, we have lowered our forecast from \$3.28 to \$2.87. Walgreens also cut its dividend by 48% this year, after 47 consecutive years of dividend growth, in order to strengthen its balance sheet. We are concerned over the debt of Walgreens. Its net debt is \$62 billion, which is nearly 5 times the market cap of the stock.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$2.90	\$3.88	\$4.59	\$5.10	\$6.02	\$5.99	\$4.74	\$5.31	\$5.04	\$3.98	\$2.87	\$3.49
DPS	\$1.28	\$1.37	\$1.46	\$1.53	\$1.64	\$1.78	\$1.84	\$1.88	\$1.91	\$1.92	\$1.00	\$1.10
Shares²	950	1,090	1,083	1,024	952	895	880	866	865	864	862	840

Walgreens has grown its earnings-per-share by 3.6% per year on average over the last decade. This was driven by a combination of factors including sales growth, a steady net profit margin and a reduction in the number of shares outstanding. In 2020, earnings-per-share fell off dramatically, with the company posting a -21% decline, mostly due to the COVID-19 pandemic. The three factors of success in the past – revenue growth, steady margins, and a lower share count – were simultaneously challenged in the short-term.

Over the long-term, an aging population and a focus on becoming a health destination should provide tailwinds. Walgreens proved to be a vital healthcare component in the pandemic as well, accounting for a significant portion of the COVID-19 vaccinations and tests. Due to the low comparison base formed in fiscal 2024 amid the fading tailwind from the pandemic and intense competition, we expect 4.0% growth of earnings-per-share over the next five years.

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	21.8	20.2	18.0	16.2	11.5	10.8	10.4	9.1	9.1	8.5	5.2	9.3
Avg. Yld.	2.0%	1.8%	1.8%	1.9%	2.4%	2.8%	3.7%	3.9%	4.2%	5.6%	6.7%	3.4%

¹ Estimated date.

² In millions

Disclosure: This analyst does not own the security discussed in this research report.



Walgreens Boots Alliance Inc. (WBA)

Updated June 27th, 2024, by Aristofanis Papadatos

During the past decade, shares of Walgreens have traded with an average price-to-earnings ratio of 13.6. However, this was during a time when the company's growth rate was much more robust. We have assumed a fair earnings multiple of 9.3, in line with the 4-year average, to better reflect a slower expected growth rate moving forward. The current 10-year low price-to-earnings ratio of 5.2 implies a valuation tailwind of 12.2% per year over the next five years.

After 47 consecutive years of dividend growth, Walgreens slashed its dividend by 48% this year. It had a decent payout ratio of less than 60% but it cut its dividend in order to reduce its debt load. Management had repeatedly confirmed its commitment to keep raising the dividend for years and hence it disappointed the shareholders. On the other hand, we view the dividend cut as a healthy decision from a long-term perspective amid a challenging business landscape.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	44%	35%	32%	30%	27%	30%	39%	35%	38%	48%	35%	32%

Walgreens' competitive advantage lies in its vast scale and network in an important and growing industry. The payout ratio is healthy and should continue to add an income ballast for investors. Furthermore, despite the reduced earnings in 2020, it should be noted that Walgreens has put together a very strong record in good times or bad. Walgreens' earnings dipped just -6.9% in 2009, as an illustration.

Final Thoughts & Recommendation

Walgreens has plunged to a 25-year low, as it is currently suffering from intense competition due to the acquisition of One Medical by Amazon and razor-thin profit margins. We expect the stock to recover in the upcoming years and offer a 20.3% average annual return over the next five years thanks to 4.0% earnings growth, a 6.7% starting yield and a 12.2% valuation tailwind. We rate the stock as a buy, but we reiterate that patience will be required, as the business model of the company is under fierce pressure and a turnaround may take years to materialize.

Total Return Breakdown by Year



Disclosure: This analyst does not own the security discussed in this research report.



Walgreens Boots Alliance Inc. (WBA)

Updated June 27th, 2024, by Aristofanis Papadatos

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue (\$B)	76	103	117	118	132	137	140	133	133	139
Gross Profit	21,569	26,753	29,874	29,162	30,792	30,076	28,017	28,067	28,265	27,072
Gross Margin	28.2%	25.9%	25.5%	24.7%	23.4%	22.0%	20.1%	21.2%	21.3%	19.4%
SG&A Exp.	17,992	22,400	23,910	23,813	24,694	25,242	27,045	24,586	27,295	34,205
D&A Exp.	1,316	1,742	1,718	1,654	1,770	2,038	1,927	1,973	1,990	2,257
Operating Profit	3,577	4,353	5,964	5,349	6,098	4,834	972	3,481	970	(7,133)
Op. Margin	4.7%	4.2%	5.1%	4.5%	4.6%	3.5%	0.7%	2.6%	0.7%	-5.1%
Net Profit	1,932	4,220	4,173	4,078	5,024	3,982	456	2,542	4,337	(3,080)
Net Margin	2.5%	4.1%	3.6%	3.4%	3.8%	2.9%	0.3%	1.9%	3.3%	-2.2%
Free Cash Flow	2,787	4,413	6,522	5,904	6,896	3,892	4,110	4,176	2,165	141
Income Tax	1,526	1,056	997	760	998	588	360	667	(30)	(1,858)

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	37,250	68,782	72,688	66,009	68,124	67,598	87,174	81,285	90,124	96,628
Cash & Equivalents	2,646	3,000	9,807	3,301	785	1,023	516	1,193	1,358	728
Acc. Receivable	3,218	6,849	6,260	6,528	6,573	7,226	7,132	5,663	5,017	5,381
Inventories	6,076	8,678	8,956	8,899	9,565	9,333	9,451	8,159	8,353	8,257
Goodwill & Int.	3,539	28,723	25,829	25,788	28,697	27,436	26,021	22,358	33,010	41,822
Total Liabilities	16,633	37,482	42,407	37,735	41,435	43,446	66,038	57,463	59,716	68,138
Accounts Payable	4,315	10,088	11,000	12,494	13,566	14,341	14,458	11,136	11,255	12,635
Long-Term Debt	4,490	14,383	19,028	12,935	14,397	16,836	15,742	8,981	11,675	9,063
Total Equity	20,513	30,861	29,880	27,466	26,007	23,512	20,637	23,419	25,275	20,021
D/E Ratio	0.22	0.47	0.64	0.47	0.55	0.72	0.76	0.38	0.46	0.45

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	5.3%	8.0%	5.9%	5.9%	7.5%	5.9%	0.6%	3.0%	5.1%	-3.3%
Return on Equity	9.7%	16.4%	13.7%	14.2%	18.8%	16.1%	2.1%	11.5%	17.8%	-13.6%
ROIC	7.8%	11.9%	8.8%	9.0%	12.2%	9.7%	1.2%	7.3%	11.5%	-7.7%
Shares Out.	950	1,090	1,083	1,024	952	895	880	866	866	863
Revenue/Share	79.15	98.15	107.55	109.61	132.20	148.20	158.51	152.94	153.25	161.12
FCF/Share	2.89	4.19	5.98	5.47	6.93	4.21	4.67	4.82	2.50	0.16

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.